Savient drug delivery, metabolic news

SVNT plans to divest its Israeli operations, including subsidiary Bio-Technology General Ltd. (Rehovot, Israel), to focus on development of prosaptide for peripheral neuropathic pain and Puricase pegylated urate oxidase for severe refractory gout. Prosaptide is a peptide derived from the human nerve growth protein prosaposin. Both compounds are in Phase II testing. ...